Humatrope

Phase 3Small molecule

Eli Lilly

Humatrope is one of 40 small molecule programs targeting Turner syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Turner SyndromeActive, not recruiting

Osteogenesis ImperfectaActive, not recruiting

Turner SyndromePhase 2

Active, not recruiting

Osteogenesis ImperfectaPhase 3

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Osteogenesis Imperfecta

#DrugCompanyPhaseTrials

Zometa

Pfizer

Approved

7 2

Neoral

Novartis

Approved

—3

Aredia

HHikma Pharmaceuticals LLC

Approved

2 4

Fosamax

OOrganon and Co

Approved

2 5

Forteo

AAlmaject

Approved

2 6

Busulfex

Akero Therapeutics

Approved

—7

Cytoxan

BBaxter Healthcare Corporation

Prolia

2 9

Risedronate Sodium

Sanofi

Phase 3

2 10

Genotropin

EMD Serono

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Turner syndrome2 trials

The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00001343·80 enrolled

Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT00266656·69 enrolled

Rehabilitation1 trial

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

Terminated·TThe University of Texas Medical Branch, Galveston·Phase 2/3·NCT00675714·1,126 enrolled

Osteogenesis Imperfecta1 trial

Growth Hormone Therapy in Osteogenesis Imperfecta

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 3·NCT00001305·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Humatrope. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Humatrope compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Humatrope. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Eli Lilly

Humatrope

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Turner syndrome2 trials

Rehabilitation1 trial

Osteogenesis Imperfecta1 trial

References

Drug Info

Quick Facts

Related News